Wilson Fish Bridge to Employment Program
- Response deadline
- Aug 10, 2026 Closed
- Date posted
- Jul 10, 2026
- Source
- Open notice
Description
The Wilson Fish Bridge to Employment Program (WF B2E) provides funds to ensure recipients of Refugee Cash Assistance (RCA) can access required employment services as outlined in the Immigration and Nationality Act. ORR"s primary strategy for ensuring access to these required services in most states is through the Refugee Support Services (RSS) program. Beginning in FY 2027, RSS will no longer be available in select states. The WF B2E program provides required employment training and placement services, as well as English language training, to recipients of RCA in the states where RSS will no longer operate. Services provided under this program are only available to individuals within the first 36 months after they either arrive in the United States or within the first 36 months they receive an ORR-eligible status. Approved projects will fund required services either directly or through subawards. Details on the states in which this program will operate will be available in the forthcoming NOFO.
Classifications
- NAICS93.583
Documents (1)
- hhs-2026-acf-orr-rw-0008-v5.pdfapplication/pdf327 KBNot yet available
Contacts
Similar contracts
- Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)Due Mar 5, 2029
- NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed)Due May 26, 2027
- Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)Due Jan 10, 2028
- Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Due Feb 8, 2028
- NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food SpecimensDue Apr 1, 2027
- Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)Due Jul 14, 2026